Artificial intelligence may predict ovarian cancer recurrence — a large study puts it to the test
NCT ID NCT07721675
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study looks at whether artificial intelligence and detailed molecular analysis can help predict how high-grade serous ovarian cancer will behave after surgery. Researchers will analyze tumor images, genetic data, and patient records from 1,300 women to build a model that forecasts recurrence and survival. The goal is to better understand the tumor's immune environment and improve personalized care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a personalized AI tool that predicts ovarian cancer recurrence and guides treatment decisions.
- What could go wrong
- This is an observational study, not a treatment trial. The AI model may not be accurate enough for clinical use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with histologically confirmed high-grade serous ovarian carcinoma (HGSOC)
- Ages
-
18 to 80 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed high-grade serous ovarian carcinoma using resection specimens. * Well-preserved surgical paraffin-embedded tumor specimens. * Complete clinical information and survival follow-up data. Exclusion Criteria: * Received preoperative neoadjuvant treatment. * Poor preservation of surgical paraffin specimens. * Incomplete clinical information and survival follow-up data. * With concurrent malignancies other than high-grade serous ovarian carcinoma.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High-grade serous ovarian carcinoma (hgsoc) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.